PerkinElmer’s Advanced Offering Reduces Assay Time By Up to 50 Percent and Enhances Detection Process for Life Science Researchers
TGR BioSciences, a leading innovator of immunoassay technologies and products, today announced a collaboration with PerkinElmer, Inc. in PerkinElmer’s launch of its AlphaLISA® SureFire® Ultra™ assays. These solutions are designed to reduce assay time by up to 50 percent and to improve the protein phosphorylation detection process. This is a critical process for helping life science professionals obtain more accurate results in biotherapeutic drug discovery research.
Combining Innova’s Lightning-Link® conjugation kits with TGR’s CaptSure™ ELISA technology simplifies ELISA development and improves sensitivity.
Cambridge, UK and Adelaide, Australia, 16 January 2014: TGR BioSciences Pty Ltd (TGR), a life sciences company focused on the development of rapid, high sensitivity ELISA systems using their CaptSure technology, and Innova Biosciences (Innova), a specialist provider of bioconjugation systems, announced that they have entered into an agreement to promote and co-market each other’s highly complementary technologies, providing customers with a major step forward in simplifying the ELISA development process, while improving sensitivity and reducing costs.
TGR has determined that combining Innova’s Lightning-Link conjugation kits for the horseradish peroxidase (HRP) labelling of antibodies with its CaptSure technology in the development of ELISA systems maximises assay sensitivity, whilst enabling the development of a wide range of ELISA assays rapidly and cost effectively. As part of the agreement Innova customers will be introduced to the CaptSure technology, with the assurance that it will work alongside the Lightning-Link reagents. Similarly, TGR customers will receive a recommendation for Lightning-Link, with the knowledge that it will be available for licensing to them, should they choose to use it alongside CaptSure products.
TGR’s CaptSure technology simplifies ELISA assays to one-step procedures, making them much faster and easier to carry out. Both assay antibodies are added to analyte at once, and after a single wash step the HRP substrate is added to develop the signal. Importantly, costs of manufacture are greatly reduced, since only a single assay plate is required (coated with CaptSure reagent) rather than a different plate for each target, and the system also requires much less assay antibodies.
Innova’s Lightning-Link conjugation system provides the ability to label antibodies with only 30 seconds hands-on time, whilst offering 100% yields and enhanced sensitivity over traditional labelling techniques and over other conjugation systems on the market.
TGR BioSciences Pty Ltd (TGR), a leading developer of advanced cell based assay technologies, is pleased to announce a license agreement with Abcam plc, of Cambridge, UK, a producer and distributor of high quality protein research tools. Under the agreement Abcam will develop and manufacture immunoassay products that incorporate TGR’s proprietary CaptSure™ assay technology. Immunoassays incorporating CaptSure are highly sensitive, offer considerable time savings, and are easy to perform when compared with conventional sandwich immunoassays.
James Murray, General Manager of Abcam Eugene commented: “We are pleased to have signed the license agreement with TGR. This innovative technology will enable Abcam to continue to develop its high quality immunoassay range by providing even greater choice to customers.”
“We’re extremely pleased that Abcam, a company at the forefront of product supply and support, has recognised the significant advantages afforded by our CaptSure immunoassay technology,” says Anne Hinton, CEO at TGR BioSciences. “Abcam is recognized around the world for providing the highest quality products and services to the Life Science community, and we are very excited to see Abcam incorporating our technology in their immunoassay products.”
TGR is delighted to announce that Dr Antony Sheehan, Principal Scientist at TGR, has been awarded the prestigious 2012 BioSA Young Achiever award. The award was presented to Dr Antony Sheehan by the Minister for Science and Information Economy, the Hon Grace Portolesi, MP, at the AusBiotech Business Development Workshop and Forum Welcome Reception on March 2019.
The award recognises Dr Sheehan’s contribution to TGR’s scientific development, commercial strategy, and his leadership skills.
Dr Sheehan joined TGR BioSciences in 2007, initially appointed as a senior scientist. Since joining TGR, Dr Sheehan has played a key role in the development of TGR’s CaptSure™ sandwich immunoassay platform which is attracting major international attention, and currently leads the R&D and product development teams.
Dr Sheehan plays a key role in aligning TGR’s technical workplans with its commercial goals and is committed to driving innovation in the research sector, particularly in the field of protein detection technologies.
For more information, contact;
Anne Hinton, CEO
email@example.com, +61 8 8354 6174
TGR BioSciences wishes to announce the transaction to facilitate the exit of the Nanyang Innovation Fund and Statewide Superannuation has been completed. The early investment by these shareholders was essential in assisting the Company to develop its current technologies. The Company is pleased that Management and other current shareholders were able to fund the exit transaction confirming their commitment to the Company’s business strategy.
TGR would like to recognise the substantial contribution and support given by all of its exiting shareholders. Further, the significant commitment by departing Directors John Bastian (Independent) and Simon Uzcilas (Nanyang) greatly assisted in completion of the transaction.
TGR BioSciences is a private company located in Adelaide, Australia. Established in 2001, TGR is committed to providing innovative solutions for cell-based research applications. Our scientists have expertise in cell biology, biochemistry and immunoassay design, and have developed products and services of the highest quality, which have been used successfully in drug discovery programs around the world.
For more information, contact;
Anne Hinton, CEO, TGR BioSciences
firstname.lastname@example.org, +61 8 8354 6174
Andrew Sneddon, Chairman, TGR BioSciences
The TGR Board wish to advise that they have appointed Ms Anne Hinton as CEO of the company effective 1 February 2012. Anne, previously TGR’s CFO/COO, brings significant commercial experience having been with the company for 10 years, and prior to that held management consulting roles in her own business and for KPMG.
Ms Hinton will succeed Dr Leanna Read, who has resigned from the company from January 31, 2012 after leading the company for over 10 years. Leanna, the founding CEO of TGR, considers that it is timely to hand over the reins and move on to new challenges.
The Board would like to thank Leanna for her considerable efforts in leading the company to a position where it is held in high regard in the international biotechnology industry.
TGR commissioned Micronaut’s renowned microscopist and artist, Martin Oeggerli, to produce an enhanced scanning electron microscope image of a human cancer cell.
The cancer cell image, © Micronaut 2010, has been awarded first prize in the ‘Images of Research’ category for Outstanding Scientific Photography in 2010.
With great sadness, we learnt that our Director and Venture Capital Investor, Dr Mike Hirshorn, passed away on November 18, 2011 after a long battle with cancer.
Mike had been a Director of TGR since he first invested in our company in 2005 through his venture capital fund, Nanyang Innovation Fund. Ever since, he has been a tireless supporter of TGR, providing us with the unparalled benefit of his 30 years experience in establishing, building and investing in biotechnology companies. He brought us much more than investment dollars – we also gained his mentorship, enthusiasm, encouragement, attention to detail and capacity to think outside the square. We particularly appreciated his unwavering support during the difficult period when TGR changed directions following an inconclusive clinical trial.
Mike initially trained as a medical doctor. After a brief stint in medical practice, his passion for commercial application of science led him into the corporate sector and to complete formal qualifications in business and finance. His accomplishments have been many. He can truly be considered a pioneer of Australia’s medical devices sector, with achievements including founder and CEO of Cochlear Ltd and co-founding director of Resmed, two global leading medical device companies. His impact on commercialisation of medical technology has been widely recognised through appointment to numerous industry and government boards, membership of the Young Presidents’ Organisation, and prestigious awards including the 1988 BRW Businessman of the Year for Technology and a 2004 Order of Australia Medal.
More recently, Mike resolved to use his experience to help foster the development of the Australian biotech industry. This led him to take up a new career in venture capital. As remarked by TGR’s former chairman, Bob Moses – “You could connect with Mike because his integrity and lack of any pretence was immediately obvious….. Those wishing to succeed in either or both technology development and funds management could do no better than to try to emulate Mike Hirshorn.”
Mike bravely battled with his cancer for over a decade. It never ceased to amaze us that he could consider his health so objectively, and not let it interfere with his work. In fact, many of his associates were unaware of his illness until a very late stage.
Everyone at TGR will miss Mike’s wonderful leadership, guidance, wit and friendship. An extremely hard man to replace! Farewell and many thanks, Mike.